Drug Subsidies & Schemes

 

01 Apr 2020

The Ministry of Health (MOH) provides subsidies for drugs at our public hospitals, specialist outpatient clinics and polyclinics to ensure that patients have access to effective medications for common medical conditions in Singapore.

Expand All | Collapse All

Who is Eligible?


Patients receive drug subsidies and assistance based on their subsidy and means-test status, and the scheme under which the drug is covered (e.g. Standard Drug List (SDL), Medication Assistance Fund (MAF)).

What drugs can I claim for?


If you need financial support to pay for the medications you are taking, check the following list to see if they are included.


 

List of Drugs* (as of 1 April 2020)

* The drug availability at each healthcare institution varies, depending on the clinical conditions commonly managed by the institution and the drugs usually prescribed by the doctors.

Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Absolute Alcohol Injection 100% SDL
Acetazolamide Tablet 250 mg SDL
Acetic acid Ear drops 2%, 3%, 4%, 5% SDL
Acetylcysteine Injection 2 g/10 mL, 5 g/25 mL SDL
Aciclovir Concentrate for infusion 250 mg/10 mL SDL
Aciclovir Infusion 250 mg SDL
Aciclovir Eye ointment 3% SDL
Acitretin Capsule 10 mg, 25 mg SDL
Adalimumab Prefilled pen 40 mg/0.8 mL MAF Checklist to be completed.
1) Treatment of adult patients with rheumatoid arthritis
2) Treatment of adult patients with ankylosing spondylitis
3) Treatment of adult patients with psoriatic arthritis
4) Treatment of juvenile idiopathic arthritis
5) Treatment of adult patients with Crohn's disease
6) Treatment of children (6 years and older) with Crohn's disease
7) Treatment of adult patients with ulcerative colitis
8) Treatment of adult patients with chronic plaque psoriasis
9) Treatment of hidradenitis suppurativa
Adalimumab Prefilled syringe 40 mg/0.8 mL MAF Checklist to be completed.
1) Treatment of adult patients with rheumatoid arthritis
2) Treatment of adult patients with ankylosing spondylitis
3) Treatment of adult patients with psoriatic arthritis
4) Treatment of juvenile idiopathic arthritis
5) Treatment of adult patients with Crohn's disease
6) Treatment of children (6 years and older) with Crohn's disease
7) Treatment of adult patients with ulcerative colitis
8) Treatment of adult patients with chronic plaque psoriasis
9) Treatment of hidradenitis suppurativa
Adefovir Dipivoxil Tablet 10 mg SDL
Adrenaline Injection 1:1,000 (1 mg/mL), 1:10,000 (1 mg/10 mL) SDL
Albendazole Oral suspension 400 mg/10 mL SDL
Albendazole Tablet 400 mg SDL
Alendronic Acid Tablet 10 mg, 70 mg SDL
Alendronic Acid & Colecalciferol Tablet Alendronic Acid 70 mg + Colecalciferol 2,800 international units, Alendronic Acid 70 mg + Colecalciferol 5,600 international units MAF 1) For patients with osteoporosis (T-score ≤ -2.5)
2) For patients with osteopenia (T-score ≤ -1.5) and a history of non-trauma induced fracture
Alfacalcidol Capsule 0.25 mcg, 1 mcg SDL
Alfacalcidol Oral drops 2 mcg/mL SDL
Alfacalcidol Tablet 0.25 mcg, 1 mcg SDL
Alfuzosin Hydrochloride Tablet 10 mg SDL
Alginic Acid, Sodium Bicarbonate, Aluminium Hydroxide & Magnesium Trisilicate Chewable tablet Alginic Acid 500 mg + Sodium Bicarbonate 170 mg + Aluminium Hydroxide (dried gel) 100 mg + Magnesium Trisilicate 25 mg SDL
Allopurinol Tablet 100 mg, 300 mg SDL
Alteplase Infusion 50 mg/50 mL SDL
Aluminium Hydroxide Tablet 600 mg SDL
Aluminium Hydroxide, Magnesium Trisilicate & Simeticone Chewable tablet Aluminium Hydroxide 250 mg + Magnesium Trisilicate 250 mg + Simeticone 30 mg SDL
Aluminium Hydroxide, Magnesium Trisilicate & Simeticone Oral suspension Aluminium Hydroxide 400 mg/5 mL + Magnesium Trisilicate 400 mg/5 mL + Simeticone 30 mg/5 mL SDL
Aluminium Oxide Oral suspension 4% SDL
AmbrisentanTablet5 mg, 10 mgMAFTreatment of adults with a confirmed diagnosis of WHO Functional Class II or III pulmonary arterial hypertension (PAH) who have one of the following PAH aetiologies:
• Idiopathic PAH
• Heritable or familial PAH
• PAH associated with connective tissue disease
• Anorexigen-induced PAH
• PAH associated with HIV infection
Amikacin Injection 500 mg/2 mL SDL
Amiloride & Hydrochlorothiazide Tablet Amiloride Hydrochloride 5 mg + Hydrochlorothiazide 50 mg SDL
Amino Acids Infusion 5%, 10% SDL
Aminobenzoic Acid Ointment 10% SDL
Aminophylline Injection 250 mg/10 mL SDL
Amiodarone Hydrochloride Injection 50 mg/mL SDL
Amiodarone Hydrochloride Tablet 200 mg SDL
Amitriptyline Tablet 10 mg, 25 mg SDL
Amlodipine Tablet 5 mg, 10 mg SDL
Amoxicillin Capsule 250 mg SDL
Amoxicillin Oral suspension 125 mg/5 mL, 250 mg/5 mL SDL
Amoxicillin & Clavulanic Acid Injection Amoxicillin 500 mg + Clavulanic Acid 100 mg, Amoxicillin 1 g + Clavulanic Acid 200 mg SDL
Amoxicillin & Clavulanic Acid Oral suspension Amoxicillin 200 mg/5 mL + Clavulanic Acid 28.5 mg/5 mL, Amoxicillin 600 mg/5 mL + Clavulanic Acid 42.9 mg/5 mL SDL
Amoxicillin & Clavulanic Acid Tablet Amoxicillin 500 mg + Clavulanic Acid 125 mg, Amoxicillin 875 mg + Clavulanic Acid 125 mg SDL
Amphotericin B Injection 50 mg SDL
Amphotericin B Eye drops 1 mg/mL SDL
Ampicillin Injection 0.5 g SDL
Anastrozole Tablet 1 mg MAF Treatment of hormone receptor positive, postmenopausal women with early and advanced breast cancer
Antazoline Hydrochloride & Tetryzoline Hydrochloride Eye drops Antazoline Hydrochloride 0.5 mg/mL + Tetryzoline Hydrochloride 0.4 mg/mL SDL
Anti-Rabies Immunoglubulin Injection 300 units/2 mL SDL
ApixabanTablet2.5 mg, 5 mgMAF1) Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)* and CHA2DS2-VASc score of 1 or more for men, and 2 or more for women
*This excludes patients with rheumatic mitral stenosis or prosthetic heart valves
2) Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE in adults. MAF assistance does not apply to patients with isolated distal DVT
Aprepitant Capsule 80 mg, 125 mg MAF Prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
Aprepitant Capsule 80 mg & 125 mg (Tripack) MAF Prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
Aqueous Cream Cream Emulsifying Ointment 30% with either Chlorocresol 0.1% or Phenoxyethanol 0.1% SDL
Ascorbic Acid Tablet 100 mg SDL
Ascorbic Acid Injection 1 g/20 mL, 500 mg/5 mL SDL
Aspirin Tablet 100 mg, 300 mg SDL
Atenolol Tablet 50 mg, 100 mg SDL
Atorvastatin Tablet 10 mg, 20 mg, 40 mg, 80 mg SDL
Atracurium Injection 25 mg/2.5 mL, 50 mg/5 mL SDL
Atropine Sulfate Eye drops 0.5%, 1% SDL
Atropine Sulfate Injection 0.6 mg/mL, 6 mg/mL SDL
Azathioprine Tablet 50 mg SDL
Azithromycin Extended-release oral suspension 2 g SDL
Azithromycin Injection 500 mg SDL
Azithromycin Oral suspension 200 mg/5 mL SDL
Azithromycin Tablet 250 mg SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Bacillus Calmette-Guerin Solution for intravesical use 27 mg, 81 mg SDL
Bacillus Calmette-Guerin Vaccine Injection 0.75 mg/mL SDL
Bacitracin, Polymyxin & Neomycin Powder Bacitracin Zinc 400 u/g + Polymyxin B Sulfate 5,000 u/g + Neomycin Sulfate 3,400 u/g SDL
Beclomethasone Inhaler 250 mcg/dose SDL
Beclomethasone Dipropionate Inhaler 50 mcg/dose SDL
Bentonite Suspension 7% SDL
Benzalkonium Chloride & Cetrimide Cream Benzalkonium Chloride 0.01% + Cetrimide 0.2% SDL
Benzathine Benzylpenicillin Injection 2.4 million international units SDL
Benzatropine Injection 2 mg/2 mL SDL
Benzatropine Mesilate Tablet 2 mg SDL
Benzhexol Hydrochloride Tablet 2 mg SDL
Benzoyl Peroxide Gel 2.5%, 5%, 10% SDL
Benzoyl Peroxide Lotion 5%, 10% SDL
Benzyl Benzoate Topical emulsion 25% SDL
Benzylpenicillin Sodium Eye drops (preservative-free) 2,500 international units/mL SDL
Benzylpenicillin Sodium Injection 1 million international units, 5 million international units SDL
Betahistine Mesilate Tablet 6 mg SDL
Betamethasone (as Valerate) Scalp lotion 0.1% SDL
Betamethasone (as Valerate) Cream 0.0125%, 0.025%, 0.05%, 0.1% SDL
Betamethasone (as Valerate) Ointment 0.025%, 0.05%, 0.1% SDL
Betamethasone (as Valerate) & Clioquinol Cream Betamethasone 0.025% + Clioquinol 3%, Betamethasone 0.05% + Clioquinol 3%, Betamethasone 0.1% + Clioquinol 3% SDL
Betamethasone Sodium Phosphate Eye/ear drops 0.1% SDL
Betamethasone Sodium Phosphate Eye/ear drops 0.1% SDL
Betaxolol Eye drops 0.25% SDL
Bethanechol Chloride Tablet 10 mg SDL
Bevacizumab Intravitreal injection 25 mg/mL MAF 1) Treatment of adults with visual impairment due to neovascular (wet) age-related macular degeneration
2) Treatment of adults with visual impairment due to macular oedema secondary to central or branch retinal vein occlusion
3) Treatment of adults with visual impairment due to diabetic macular oedema
Bisacodyl Enteric-coated tablet 5 mg SDL
Bisacodyl Rectal suppository 10 mg SDL
Bismuth Subcitrate Tablet 120 mg, 300 mg SDL
Bismuth Subgallate Rectal suppository Bismuth Subgallate 200 mg + Zinc Oxide 120 mg SDL
Bismuth Subnitrate Paste 10% SDL
Bisoprolol Fumarate Tablet 2.5 mg, 5 mg SDL
Bleomycin Injection 15 mg SDL
Boric Acid, Resorcinol & Phenol Paint Boric Acid 0.8% + Resorcinol 8% + Phenol 4% SDL
Bortezomib Injection 3.5 mg MAF Checklist to be completed.
For primary induction in newly diagnosed patients with symptomatic multiple myeloma
Botulinum toxin type A complex (Botox) Injection 50 units, 100 units MAF 1) For adults with focal spasticity of the upper limbs due to stroke, who have Modified Ashworth Scale of 2 or more at the target muscle intended for botulinum toxin A treatment, and do not have the affected joint permanently fixed in position due to fibrotic shortening of the target muscle and are concurrently receiving physiotherapy

2) For adults with cervical dystonia, blepharospasm or hemifacial spasm

3) For children aged 2 years or older, with focal spasticity of the upper or lower limbs (including dynamic equinus foot deformity) due to cerebral palsy, and who do not have significant joint contractures (i.e. the affected joint is not permanently fixed in position due to shortening of the target muscle); and are concurrently receiving supportive therapy (e.g. physiotherapy or occupational therapy)
Brimonidine Tartrate Eye drops 0.15% SDL
Bromocriptine Tablet 2.5 mg SDL
Buclizine Hydrochloride Tablet 25 mg SDL
Budesonide Powder inhaler 100 mcg/dose, 200 mcg/dose SDL
Bupivacaine Hydrochloride (hyperbaric) Injection 0.5% (in dextrose 8%) SDL
Bupivacaine Hydrochloride (isobaric) Injection 0.5% SDL
Buprenorphine Sublingual tablet 0.2 mg SDL
Busulfan Injection 60 mg SDL
Busulfan Tablet 2 mg SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Cabergoline Tablet 0.5 mg MAF As a 2nd line agent for the management of hyperprolactinaemia in patients who have failed to respond or who are unable to tolerate bromocriptine
Calamine Lotion Calamine 15% SDL
Calamine & Menthol Lotion Calamine 15% + Menthol 0.4% SDL
Calcipotriol Cream 50 mcg/g SDL
Calcipotriol Ointment 50 mcg/g SDL
Calcipotriol Scalp solution 50 mcg/mL SDL
Calcipotriol & Betamethasone Gel Calcipotriol 50 mcg/g + Betamethasone (as Diproprionate) 0.5 mg/g SDL
Calcipotriol & Betamethasone Ointment Calcipotriol 50 mcg/g + Betamethasone (as Diproprionate) 0.5 mg/g SDL
Calcitriol Capsule 0.25 mcg, 0.5 mcg SDL
Calcium Syrup 20 mg to 23 mg Ca2+/mL SDL
Calcium Acetate Tablet 667 mg SDL
Calcium Carbonate Chewable tablet 1.25 g SDL
Calcium Carbonate Tablet 625 mg SDL
Calcium Carbonate & Colecalciferol Tablet Calcium Carbonate 450 mg + Colecalciferol 5 mcg SDL
Calcium Chloride Dihydrate Injection 10% SDL
Calcium Gluconate Injection 10% SDL
Calf Blood Extract (deproteinised) Eye gel 8.3 mg/g SDL
CalfactantIntratracheal suspension105 mg/3 mL, 210 mg/6 mL  SDL 
Candesartan Cilexetil Tablet 4 mg, 8 mg, 16 mg MAF Treatment of patients with heart failure who cannot tolerate angiotensin converting enzyme inhibitors
Capecitabine Tablet 150 mg, 500 mg SDL
Captopril Tablet 12.5 mg, 25 mg SDL
Carbamazepine Controlled-release tablet 200 mg, 400 mg SDL
Carbamazepine Syrup 100 mg/5 mL SDL
Carbamazepine Tablet 200 mg SDL
Carbimazole Tablet 5 mg SDL
Carboplatin Injection 150 mg/mL, 10 mg/mL SDL
Carmustine Injection 100 mg SDL
Carvedilol Tablet 6.25 mg, 12.5 mg, 25 mg SDL
Cefalexin Capsule 250 mg SDL
Cefalexin Oral suspension 125 mg/5 mL SDL
Cefazolin Injection 1 g SDL
Ceftazidime Injection 1 g SDL
Ceftriaxone Injection 250 mg, 1 g, 2 g SDL
CelecoxibCapsule200 mgSDL 
Cetirizine Solution 1 mg/mL SDL
Cetrimide Topical solution 1% SDL
Cetrimide Shampoo 5% SDL
Charcoal (activated)Capsule200 mgSDL 
Charcoal (activated) Granules 50 g SDL
Charcoal (activated) Oral suspension 200 mg/mL (in sorbitol 70%) SDL
Charcoal (activated) Tablet 200 mg, 250 mg SDL
Chloral Hydrate Oral solution 200 mg/5 mL, 500 mg/5 mL SDL
Chlorambucil Tablet 2 mg SDL
Chloramphenicol Capsule 250 mg SDL
Chloramphenicol Eye drops 0.5% SDL
Chloramphenicol Eye ointment 1% SDL
Chlordiazepoxide Tablet 5 mg SDL
Chlorhexidine Acetate Irrigation solution 0.02% SDL
Chlorhexidine Gluconate Cream 1% SDL
Chlorhexidine Salt Mouthwash 0.2% SDL
Chlorhexidine Salt Topical solution 0.05%, 0.1% SDL
Chlorhexidine Salt Topical solution 4% SDL
Chlorhexidine Salt Mouthwash 0.2% SDL
Chlorhexidine Salt & Alcohol Topical solution Chlorhexidine Salt 0.1% + Alcohol 70%, Chlorhexidine Salt 0.5% + Alcohol 70% SDL
Chlorhexidine Salt & Cetrimide Topical solution Chlorhexidine Salt 0.015% + Cetrimide 0.15% SDL
Chloroquine Phosphate Tablet 150 mg SDL
Chlorpheniramine Syrup 4 mg/5 mL SDL
Chlorpheniramine Tablet 4 mg SDL
Chlorpromazine Injection 50 mg/2 mL SDL
Chlorpromazine Tablet 25 mg, 100 mg SDL
Chlorpropamide Tablet 250 mg SDL
Chlortetracycline Eye ointment 1% SDL
Choline Salicylate Oral gel 9% SDL
Ciclosporin Capsule 10 mg, 25 mg, 100 mg SDL 1) Prevention of organ rejection in bone marrow and solid organ transplant
2) Treatment of primary nephrotic syndrome
3) Treatment of psoriasis
Ciclosporin Oral solution 100 mg/mL SDL 1) Prevention of organ rejection in bone marrow and solid organ transplant
2) Treatment of primary nephrotic syndrome
3) Treatment of psoriasis
Cimetidine Injection 200 mg/2 mL, 150 mg/mL SDL
Cimetidine Tablet 200 mg SDL
Ciprofloxacin Tablet 250 mg, 500 mg SDL
Ciprofloxacin Eye/ear drops 0.3% SDL
Ciprofloxacin Infusion 2 mg/mL SDL
Cisplatin Concentrate for infusion 50 mg/50 mL SDL
Citric Acid Monohydrate & Potassium Citrate Oral solution Citric Acid Monohydrate 0.25 g/5 mL + Potassium Citrate 1.5 g/5 mL SDL
Clarithromycin Modified-release tablet 500 mg SDL
Clarithromycin Tablet 250 mg, 500 mg SDL
Clarithromycin Injection 500 mg SDL
Clarithromycin Oral suspension 125 mg/5 mL SDL
Clidinium & Chlordiazepoxide Tablet Clidinium Bromide 2.5 mg + Chlordiazepoxide 5 mg SDL
Clindamycin Capsule 150 mg SDL
Clindamycin Injection 150 mg/mL SDL
Clomiphene Tablet 50 mg SDL
Clomipramine Tablet 25 mg SDL
Clonazepam Tablet 0.5 mg, 2 mg SDL
Clopidogrel Tablet 75 mg SDL
Clotrimazole Cream 1% SDL
Clotrimazole Lotion 1% SDL
Clotrimazole Powder 1% SDL
Clotrimazole Vaginal tablet 100 mg SDL
Cloxacillin Capsule 250 mg SDL
Cloxacillin Injection 250 mg, 500 mg SDL
Cloxacillin Syrup 125 mg/5 mL SDL
Clozapine Tablet 25 mg, 100 mg SDL
Coal Tar Cream 5%, 10%, 15% SDL
Coal Tar Lotion 20% SDL
Coal Tar Shampoo 25% SDL
Coal Tar & Salicylic Acid Ointment Coal Tar 5% + Salicylic acid 2%, Coal Tar 10% + Salicylic acid 2%, Coal Tar 15% + Salicylic acid 2% SDL
Cocaine Solution 10% SDL
Cocois Compound Ointment Coal Tar Solution 10% + Camphor 2% + Sulphur 4% + Salicylic Acid 2% SDL
Codeine & Promethazine Syrup Codeine Phosphate 18 mg/10 mL + Promethazine 7.2 mg/10 mL SDL
Codeine Phosphate Tablet 30 mg SDL
Colchicine Tablet 500 mcg SDL
Colecalciferol Tablet 1,000 units SDL
Colestyramine Powder for oral suspension 4 g SDL
Compound Diphenhydramine Syrup Ranging from
5 mg/5 mL to
14 mg/5 mL		 SDL
Compound Polyethylene Glycol (Fortrans) Oral powder - SDL
Compound Sodium Lactate Infusion - SDL
Conjugated Oestrogens Tablet 0.3 mg, 0.625 mg SDL
Conjugated Oestrogens Vaginal cream 0.625 mg/g SDL
Cyanocobalamin Injection 1 mg/mL SDL
Cyclophosphamide Infusion 200 mg, 1 g SDL
Cyclophosphamide Tablet 50 mg SDL
Cyproheptadine Tablet 4 mg SDL
Cytarabine Injection 20 mg/mL, 100 mg/mL SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Dacarbazine Injection 200 mg SDL
Dactinomycin Infusion 500 mcg SDL
Dantrolene Sodium Capsule 25 mg, 100 mg SDL
Dapagliflozin Tablet 5 mg, 10 mg MAF 1) Treatment of type 2 diabetes mellitus, as a dual therapy
o In combination with metformin for patients with HbA1c > 7% despite treatment with metformin monotherapy and when sulfonylureas are contraindicated, not tolerated, or the person is at significant risk of hypoglycaemia;
o In combination with a sulfonylurea for patients with HbA1c > 7% despite treatment with sulfonylurea monotherapy and when metformin is contraindicated or not tolerated;
2) Treatment of type 2 diabetes mellitus as a triple therapy
o In combination with metformin and a sulfonylurea for patients with HbA1c > 7% despite treatment with optimal doses of dual therapy
3) Treatment of type 2 diabetes mellitus in combination with insulin, with or without metformin
Dapsone Tablet 100 mg SDL
Daunorubicin Injection 20 mg SDL
Deferiprone Oral solution 100 mg/mL SDL
Deferiprone Tablet 500 mg SDL
Deferoxamine Mesilate Injection 500 mg SDL
Denosumab Prefilled syringe 60 mg/mL MAF Treatment of post-menopausal women with osteoporosis (T-score ≤ -2.5) at high risk of fracture and eGFR > 30 mL/min and who are unable to tolerate or follow the administration instructions for oral bisphosphonates
Dequalinium Chloride Lozenge 0.25 mg SDL
Desmopressin Acetate Nasal drops 0.1 mg/mL SDL
Desmopressin Acetate Nasal spray 10 mcg/dose SDL
Desmopressin Acetate Tablet 0.1 mg, 0.2 mg SDL
Dexamethasone Tablet 500 mcg, 4 mg SDL
Dexamethasone Phosphate Injection 4 mg/mL SDL
Dexmedetomidine Concentrate for infusion 200 mcg/2 mL SDL
Dextromethorphan Hydrobromide Syrup 15 mg/5 mL SDL
Dextromethorphan Hydrobromide Tablet 15 mg SDL
Dextrose & Potassium Chloride Infusion Dextrose 5% + Potassium Chloride 0.15% SDL
Dextrose & Sodium Chloride Infusion Dextrose 2.5% + Sodium Chloride 0.45%, Dextrose 3.75% + Sodium Chloride 0.23%, Dextrose 5% + Sodium Chloride 0.2%, Dextrose 5% + Sodium Chloride 0.45%, Dextrose 5% + Sodium Chloride 0.9% SDL
Dextrose Monohydrate Infusion 5%, 10%, 20%, 50% SDL
Dextrose MonohydrateInjection50%SDL 
Dextrose, Potassium Chloride & Sodium Chloride Infusion Dextrose 5% + Potassium Chloride 0.15% + Sodium Chloride 0.33%, Dextrose 5% + Potassium Chloride 0.22% + Sodium Chloride 0.45%, Dextrose 5% + Potassium Chloride 0.30% + Sodium Chloride 0.45%, Dextrose 5% + Potassium Chloride 0.15% + Sodium Chloride 0.45%, Dextrose 5% + Potassium Chloride 0.15% + Sodium Chloride 0.9% SDL
Diazepam Enema 5 mg/2.5 mL SDL
Diazepam Injection 5 mg/mL SDL
Diazepam Tablet 2 mg, 5 mg, 10 mg SDL
Dibasic Sodium Phosphate & Monobasic Sodium Phosphate Enema Dibasic Sodium Phosphate 7 g/118 mL + Monobasic Sodium Phosphate 19 g/118 mL, Dibasic Sodium Phosphate 3.5 g/59 mL + Monobasic Sodium Phosphate 9.5 g/59 mL SDL
Diclofenac Sodium Enteric-coated tablet 25 mg, 50 mg SDL
Diclofenac Sodium Injection 25 mg/mL SDL
Diclofenac Sodium Rectal suppository 12.5 mg, 25 mg, 50 mg SDL
Diclofenac Sodium Gel 1% SDL
Diethylcarbamazine Citrate Tablet 50 mg SDL
Digoxin Injection 100 mcg/mL, 250 mcg/mL SDL
Digoxin Oral solution 50 mcg/mL SDL
Digoxin Tablet 62.5 mcg, 250 mcg SDL
Digoxin-specific Antibody Fragments Injection 40 mg SDL
Diltiazem Hydrochloride Injection 10 mg, 50 mg SDL
Diltiazem Hydrochloride Sustained-release capsule 90 mg, 100 mg, 200 mg SDL
Diltiazem Hydrochloride Tablet 30 mg, 60 mg SDL
Dimercaprol Injection 50 mg/mL SDL
Diosmin & Hesperidin Tablet Diosmin 450 mg + Hesperidin 50 mg SDL
Diphenoxylate & Atropine Sulfate Tablet Diphenoxylate Hydrochloride 2.5 mg + Atropine Sulfate 25 mcg SDL
Diphtheria & Tetanus Vaccine Injection Diphtheria Toxoid Vaccine minimum 2 international units/0.5 mL + Tetanus Toxoid Vaccine minimum 20 international units/0.5 mL SDL
Diphtheria Antitoxin Injection 10,000 units SDL
Diphtheria, Tetanus & Pertussis Vaccine Injection Diphtheria Toxoid Vaccine minimum 30 international units/0.5 mL + Tetanus Toxoid Vaccine minimum 40 international units/0.5 mL + Pertussis Toxoid Vaccine 25 microgram/0.5 mL + Filamentous Haemagglutinin 25 microgram/0.5 mL + Pertactin 8 microgram/0.5 mL SDL
Dipyridamole Tablet 25 mg, 75 mg SDL
Disodium Edetate Eye drops 0.38%, 3% SDL
Dithranol Ointment 1%, 2% SDL
Dobutamine Concentrate for infusion 250 mg/5 mL, 250 mg/20 mL SDL
Docetaxel Infusion 20 mg, 80 mg, 160 mg MAF 1) For the treatment of patients with locally advanced or metastatic breast cancer.
2) In combination with doxorubicin and cyclophosphamide for the adjuvant treatment of patients with operable node-positive or operable node-negative breast cancer.
3) For the treatment of patients with locally advanced or metastatic non-small cell lung cancer.
4) In combination with prednisone or prednisolone for the treatment of patients with hormone refractory metastatic prostate cancer.
Donepezil Hydrochloride Oral disintegrating tablet 5 mg, 10 mg MAF For patients with mild to moderately severe Alzheimer's Disease who have swallowing difficulties and are unable to receive a film-coated tablet
Donepezil Hydrochloride Tablet 5 mg, 10 mg SDL
Dopamine Hydrochloride Concentrate for infusion 200 mg/5 mL SDL
Dothiepin Hydrochloride Tablet 75 mg SDL
Dothiepin Hydrochloride Capsule 25 mg SDL
Doxorubicin Hydrochloride Injection 10 mg, 50 mg SDL
Doxycycline Capsule 100 mg SDL
Droperidol Injection 2.5 mg/mL SDL
DutasterideCapsule0.5 mgSDL 
Dydrogesterone Tablet 10 mg SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Empagliflozin Tablet 10 mg, 25 mg MAF1) Treatment of type 2 diabetes mellitus, as a dual therapy
o In combination with metformin for patients with HbA1c > 7% despite treatment with metformin monotherapy and when sulfonylureas are contraindicated, not tolerated, or the person is at significant risk of hypoglycaemia;
o In combination with a sulfonylurea for patients with HbA1c > 7% despite treatment with sulfonylurea monotherapy and when metformin is contraindicated or not tolerated;
2) Treatment of type 2 diabetes mellitus as a triple therapy
o In combination with metformin and a sulfonylurea for patients with HbA1c > 7% despite treatment with optimal doses of dual therapy
3) Treatment of type 2 diabetes mellitus in combination with insulin, with or without metformin
Emulsifying Ointment Ointment - SDL
Enalapril Maleate Tablet 5 mg, 10 mg, 20 mg SDL
Enoxaparin Sodium Injection 20 mg/0.2 mL, 40 mg/0.4 mL, 60 mg/0.6 mL, 80 mg/0.8 mL SDL
Entacapone Tablet 200 mg SDL
Entecavir Oral solution 0.05 mg/mL MAF Treatment of nucleos(t)ide-naïve patients with HBeAg-positive and HBeAg-negative chronic hepatitis B infection and evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease
Entecavir Tablet 0.5 mg, 1 mg MAF Treatment of nucleos(t)ide-naïve patients with HBeAg-positive and HBeAg-negative chronic hepatitis B infection and evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease
Ephedrine Sulfate Injection 30 mg/mL SDL
Epoetin Alfa Injection 2,000 international units/0.5 mL, 4,000 international units/0.4 mL SDL
Epoetin Beta Injection 2,000 international units/0.3 mL, 4,000 international units/0.3 mL SDL
Epoprostenol (Veletri)Infusion1.5 mgMAFTreatment of pulmonary arterial hypertension (idiopathic or heritable PAH or PAH associated with connective tissue diseases) in patients with WHO Functional Class III-IV symptoms
Ergometrine Maleate Injection 500 mcg/mL SDL
Ergotamine & Caffeine Tablet Caffeine 100 mg + Ergotamine Tartrate 1 mg SDL
Erythromycin (as Ethyl Succinate) Tablet 400 mg SDL
Erythromycin (as Ethyl Succinate) Oral suspension 200 mg/5 mL SDL
Erythromycin (as Lactobionate) Infusion 500 mg, 1 g SDL
Erythromycin Stearate Enteric-coated tablet 250 mg SDL
Estradiol Vaginal tablet 10 mcg, 25 mcg SDL
Etanercept Prefilled syringe 25 mg/0.5 mL, 50 mg/mL MAF Checklist to be completed
1) Treatment of adult patients with non-radiographic axial spondyloarthritis
2) Treatment of juvenile idiopathic arthritis
3) Treatment of adult patients with chronic plaque psoriasis
Etanercept Injection 25 mg/mL MAF Checklist to be completed
1) Treatment of adult patients with non-radiographic axial spondyloarthritis
2) Treatment of juvenile idiopathic arthritis
3) Treatment of adult patients with chronic plaque psoriasis
Ethambutol Hydrochloride Tablet 100 mg, 400 mg SDL
Ethanol Solution Ethanol 95% SDL
Ethionamide Tablet 125 mg SDL
Ethyl Chloride Topical spray 88 g/100 mL SDL
Etoposide Capsule 50 mg, 100 mg SDL
Etoposide Concentrate for infusion 20 mg/mL SDL
EtoricoxibTablet60 mg, 90 mg, 120 mgSDL 
Everolimus Tablet 0.25 mg, 0.75 mg MAF For kidney transplant immunosuppression in patients with:
1) Evidence of CNI-induced nephrotoxicity on allograft biopsy OR
2) Elevated serum creatinine levels precluding the achievement of optimal therapeutic blood levels of CNI OR
3) History of CNI drug hypersensitivity
EzetimibeTablet10 mgSDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Factor Eight Inhibitor Bypassing Activity (FEIBA)Injection500 unitsSDL 
Famotidine Tablet 20 mg SDL
Fenofibrate Capsule 100 mg, 300 mg SDL
Fentanyl Injection 50 mcg/mL SDL
Fentanyl Transdermal patch 12 mcg/hr, 25 mcg/hr, 50 mcg/hr SDL
Ferric CarboxymaltoseInjection500 mg/10 mLSDL 
Ferrous Fumarate Tablet 200 mg SDL
Ferrous Gluconate Tablet 300 mg SDL
Ferrous Gluconate, Multivitamins & Minerals Capsule Ferrous Gluconate 250 mg + Vit B12 7.5 mcg + Vit C 50 mg + Folic Acid 1 mg + Sorbitol 25 mg + Copper Sulfate 200 mcg + Manganese Sulfate 200 mcg SDL
Ferrous Sulphate & Vitamin B1 & Riboflavin & Nicotinamide Tablet Ferrous Sulphate 200 mg + Vitamin B1 3 mg + Riboflavin 1.5 mg + Nicotinamide 10 mg SDL
Filgrastim Injection 30 million units/0.5 mL (300 mcg/0.5 mL), 30 million units/mL (300 mcg/mL) SDL
Finasteride Tablet 5 mg SDL
Fluconazole Capsule 50 mg, 100 mg, 150 mg SDL
Fluconazole Infusion 100 mg/50 mL SDL
Fludrocortisone Acetate Tablet 0.1 mg SDL
Flumazenil Injection 0.1 mg/mL SDL
Fluocinolone Acetonide Cream 0.003125%, 0.00625%, 0.0125%, 0.025% SDL
Fluorescein Sodium Injection 10% SDL
Fluorescein Sodium Single-use eye drops 2% SDL
Fluorouracil Injection 50 mg/mL SDL
Fluoxetine Capsule 10 mg, 20 mg SDL
Flupenthixol Decanoate Injection 20 mg/mL, 40 mg/2 mL SDL
Fluphenazine Decanoate Injection 25 mg/mL SDL
Fluticasone Propionate Inhaler 50 mcg/dose, 125 mcg/dose, 250 mcg/dose SDL
Fluvoxamine Maleate Tablet 50 mg SDL
Folic Acid Tablet 5 mg SDL
Folinic Acid Injection 10 mg/mL SDL
Formoterol & Budesonide Powder inhaler Formoterol Fumarate Dihydrate 4.5 mcg/dose + Budesonide 80 mcg/dose, Formoterol Fumarate Dihydrate 4.5 mcg/dose + Budesonide 160 mcg/dose, Formoterol Fumarate Dihydrate 9 mcg/dose + Budesonide 320 mcg/dose SDL
Furosemide Injection 10 mg/mL SDL
Furosemide Tablet 40 mg SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Gabapentin Capsule 100 mg, 300 mg, 400 mg SDL
Ganciclovir Infusion 500 mg SDL
Gelatin Succinylated & Sodium Chloride Infusion Gelatin Succinylated 4 g/100 mL + Sodium Chloride 0.701 g/100 mL SDL
Gemcitabine Infusion 200 mg, 1000 mg, 2000 mg SDL
Gemfibrozil Capsule 300 mg SDL
Gentamicin Injection 40 mg/mL SDL
Gentamicin Eye drops 0.3% SDL
Gentian Violet Paint 0.5% SDL
Glibenclamide Tablet 5 mg SDL
Gliclazide Tablet 80 mg SDL
Glipizide Tablet 5 mg SDL
Glucagon Injection 1 mg SDL
Glycerol Rectal suppository 1 g, 1.5 g, 2 g SDL
Glycerol, Methyl Salicylate, Sodium Salicylate & Thymol Compound Mouthwash Glycerol 10% + Methyl Salicylate 0.03% + Sodium Salicylate 0.52% + Thymol 0.05% SDL
Glyceryl Trinitrate Oral spray 0.4 mg/dose SDL
Glyceryl Trinitrate Patch 5 mg, 10 mg SDL
Glyceryl Trinitrate Sublingual tablet 0.5 mg SDL
Glycine Irrigation solution 1.5% SDL
Golimumab Prefilled syringe 50 mg/0.5 mL MAF Checklist to be completed
1) Treatment of adult patients with rheumatoid arthritis
2) Treatment of adult patients with ankylosing spondylitis
3) Treatment of adult patients with psoriatic arthritis
4) Treatment of adult patients with non-radiographic axial spondyloarthritis
5) Treatment of adult patients with ulcerative colitis
Golimumab Prefilled pen 50 mg/0.5 mL MAF Checklist to be completed
1) Treatment of adult patients with rheumatoid arthritis
2) Treatment of adult patients with ankylosing spondylitis
3) Treatment of adult patients with psoriatic arthritis
4) Treatment of adult patients with non-radiographic axial spondyloarthritis
5) Treatment of adult patients with ulcerative colitis
Goserelin Subcutaneous injectable implant 3.6 mg, 10.8 mg MAF LHRH agonist is recommended:
1) As primary therapy for men with locally advanced or metastatic prostate cancer
2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy
3) For men with prostate cancer who have a biochemical relapse
LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer
Griseofulvin Tablet 125 mg, 500 mg SDL
Guaifenesin Syrup 100 mg/5 mL SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Haemodialysis Concentrate 35X (Acetate Salt) Solution The diluted solution contains: Na+ 140.0 mmol/L, K+ 2.60 mmol/L, Ca2+ 1.38 mmol/L, Mg2+ 0.62 mmol/L, Cl- 102 mmol/L, HCO3- 45 mmol/L SDL
Haemodialysis Concentrate 35X (Bicarbonate) Solution (comprised 2 separate 10 L canisters: acidic & basic) Acidic concentrate: KCl 5.5 g/L, NaCl 161.0 g/L, CaCl2.2H2O 9.7 g/L, MgCl2.6H2O 3.7 g/L, CH3COOH (glacial) 8.8 g/L; Basic concentrate: NaCl 30.5 g/L, HCO3- 66.0 g/L; Final diluted solution contains: Na+ 140 mmol/L, K+ 2.0 mmol/L, Ca2+ 1.8 mmol/L, Mg2+ 0.5 mmol/L, Cl- 107.2 mmol/L, CH3COO- 4.0 mmol/L, HCO3- 35.0 mmol/L SDL
Haloperidol Injection 5 mg/mL SDL
Haloperidol Oral solution 2 mg/mL SDL
Haloperidol Tablet 0.5 mg, 1.5 mg, 5 mg SDL
Heparin Sodium Injection 1,000 units/mL, 5,000 units/mL, 25,000 units/5 mL SDL
Heparinised Saline Injection (in sodium chloride 0.9%, preservative-free) 50 international units/5 mL SDL
Hepatitis B Immunoglobulin Injection ≥ 200 international units/mL (adults), ≥100 international units/mL (children) SDL
Homatropine Hydrobromide Eye drops 2% SDL
Hydralazine Hydrochloride Tablet 10 mg, 25 mg, 50 mg SDL
Hydralazine Hydrochloride Injection 20 mg/mL SDL
Hydrochlorothiazide Tablet 25 mg SDL
Hydrocolloid (carboxymethylcellulose-containing) Dressing - SDL
Hydrocolloid (carboxymethylcellulose-containing) Gel - SDL
Hydrocortisone Cream 0.5%, 1% SDL
Hydrocortisone Lotion 0.5% SDL
Hydrocortisone Ointment 1% SDL
Hydrocortisone Tablet 10 mg SDL
Hydrocortisone (as Sodium Succinate) Injection 100 mg SDL
Hydrocortisone Acetate Rectal foam 10% SDL
Hydrocortisone Acetate & Clioquinol Cream Hydrocortisone Acetate 1% + Clioquinol 3% SDL
Hydrogen Peroxide Mouthwash 3% SDL
Hydrogen Peroxide Topical solution 3% SDL
Hydroxychloroquine Sulphate Tablet 200 mg SDL
Hydroxychloroquine Sulphate Tablet 200 mg SDL
Hydroxyprogesterone Caporate Injection 250 mg/mL SDL
Hydroxyurea Capsule 500 mg SDL
Hydroxyzine Hydrochloride Tablet 10 mg, 25 mg SDL
Hydroxyzine Hydrochloride Syrup 10 mg/5 mL SDL
Hyoscine Butylbromide Injection 20 mg/mL SDL
Hyoscine Butylbromide Tablet 10 mg SDL
Hyoscine Hydrobromide Trihydrate Injection 400 mcg/mL SDL
Hypromellose Eye drops 0.3% SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Ibuprofen Oral liquid 100 mg/5 mL SDL
Ibuprofen Tablet 200 mg SDL
Ifosfamide Infusion 1 g SDL
Imipenem & Cilastatin Infusion Imipenem 500 mg + Cilastatin 500 mg SDL
Imipramine Hydrochloride Tablet 10 mg, 25 mg SDL
Indometacin Capsule 25 mg SDL
Infliximab (Remsima) Infusion 100 mg MAF Checklist to be completed
1) Treatment of adult patients with rheumatoid arthritis
2) Treatment of adult patients with ankylosing spondylitis
3) Treatment of adult patients with psoriatic arthritis
4) Treatment of adult patients with Crohn's disease
5) Treatment of children (6 to 17 years) with Crohn's disease
6) Treatment of adult patients with ulcerative colitis
7) Treatment of children (6 to 17 years) with ulcerative colitis
8) Treatment of adult patients with chronic plaque psoriasis
Insulin Aspart Injection, penfill 100 international units/mL MAF Type 1 & 2 diabetes mellitus
Insulin Aspart Injection, prefilled pen 100 international units/mL SDL
Insulin Aspart & Insulin Aspart Protamine Injection, prefilled pen Insulin Aspart 30% + Insulin Aspart Protamine 70% SDL
Insulin Detemir Injection, prefilled pen 100 international units/mL SDL
Insulin Glargine (Basaglar) Injection, cartridge 100 international units/mL SDL
Insulin Glargine (Lantus) Injection 100 international units/mL SDL
Insulin Glargine (Lantus) Injection, penfill 100 international units/mL SDL
Insulin Glargine (Lantus) Injection, prefilled pen 100 international units/mL SDL
Insulin Glulisine Injection, prefilled pen 100 international units/mL SDL
Insulin Isophane (Human) Injection 100 international units/mL SDL
Insulin Isophane (Human) Injection, penfill 100 international units/mL SDL
Insulin Lispro Injection 100 international units/mL MAF Type 1 & 2 diabetes mellitus
Insulin Lispro Injection, penfill 100 international units/mL MAF Type 1 & 2 diabetes mellitus
Insulin Lispro Injection, prefilled pen 100 international units/mL MAF Type 1 & 2 diabetes mellitus
Insulin Lispro & Insulin Lispro Protamine Injection, penfill Insulin Lispro 25% + Insulin Lispro Protamine 75% SDL
Insulin Lispro & Insulin Lispro Protamine Injection, prefilled pen Insulin Lispro 25% + Insulin Lispro Protamine 75% MAF Type 1 & 2 diabetes mellitus
Insulin Lispro & Insulin Lispro Protamine Injection, prefilled pen Insulin Lispro 50% + Insulin Lispro Protamine 50% MAF Type 1 & 2 diabetes mellitus
Insulin Soluble & Insulin Isophane (Human) Injection Insulin Soluble 30% + Insulin Isophane 70% SDL
Insulin Soluble & Insulin Isophane (Human) Injection, penfill Insulin Soluble 30% + Insulin Isophane 70% SDL
Insulin Soluble (Human) Injection 100 international units/mL SDL
Insulin Soluble (Human) Injection, penfill 100 international units/mL SDL
Interferon Alfa-2a Injection 3 million international units/0.5 mL, 6 million international units/0.5 mL SDL
Intraperitoneal Dialysis Solution Dextrose 1.5%, 2.5% or 4.25% with Ca2+ 1.25 mmol/L, Na+ 132 mmol/L, Mg2+ 0.25 mmol/L, Cl- 95 mmol/L, Lactate 40 mmol/L; Dextrose 1.5%, 2.5% or 4.25% with Ca2+ 2.57 mmol/L, Na+ 132 mmol/L, Mg2+ 0.25 mmol/L, Cl- 96 mmol/L, Lactate 40 mmol/L SDL
Iodine Topical solution 0.5%, 1.0%, 2.5% SDL
Iodine Aqueous Oral solution Iodine 5% + Potassium iodide 10% SDL
Ipratropium Bromide Inhaler 20 mcg/dose SDL
Ipratropium Bromide Nebulisation solution 0.025% SDL
Irinotecan Hydrochloride Trihydrate Infusion 20 mg/mL SDL
Iron (as Polymaltose) Oral drops 50 mg/mL SDL
Iron (as Polymaltose)
Tablet100 mgSDL  
Iron (as Sucrose) Injection 100 mg/5 mL SDL
Isoniazid Tablet 100 mg, 300 mg SDL
Isoprenaline Hydrochloride Injection 0.2 mg/mL, 1 mg/mL SDL
Isoprenaline Sulfate Injection 0.2 mg/mL, 1 mg/mL SDL
Isosorbide Dinitrate Tablet 10 mg SDL
Isosorbide Mononitrate Sustained-release tablet 60 mg SDL
Itraconazole Capsule 100 mg SDL
Itraconazole Oral solution 10 mg/mL MAF For prophylaxis of invasive fungal infections in high risk patients (such as anticipated to have prolonged neutropenia) and haematopoietic stem cell transplant recipients
Ivabradine Tablet 5 mg, 7.5 mg MAF Treatment of chronic heart failure in patients with New York Heart Association (NYHA) class II to IV stable chronic heart failure with systolic dysfunction (LVEF of 35% or less), and who are in sinus rhythm with a heart rate of 75 bpm or more, and who are given concomitant standard medical management including the maximum tolerated dose of beta-blocker therapy, angiotensin converting enzyme inhibitors and aldosterone antagonists, unless contraindicated or not tolerated
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Kanamycin Injection 1 g SDL
Kaolin, Magnesium Carbonate (light) & Sodium Bicarbonate Oral suspension Kaolin 20% + Magnesium Carbonate (light) 5% + Sodium Bicarbonate 5% SDL
Ketoprofen Enteric-coated tablet 100 mg SDL
Ketoprofen Slow-release tablet 200 mg SDL
Ketoprofen Gel 2.5% SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Lactulose Syrup 3.3 g/5 mL, 3.35 g/5 mL SDL
Lamivudine Tablet 100 mg SDL
Lamotrigine Dispersible tablet 5 mg SDL
Lamotrigine Tablet 50 mg, 100 mg SDL
Land Snakes Antivenom Concentrate for infusion - SDL
L-Asparaginase Injection 10,000 international units SDL
Latanoprost Eye drops 0.005% SDL
Leflunomide Tablet 10 mg, 20 mg, 100 mg MAF 1) Treatment of active psoriatic arthritis where other disease modifying drugs are ineffective and/ or inappropriate
2) Treatment of active rheumatoid arthritis where other disease modifying drugs are ineffective and/ or inappropriate
Letrozole Tablet 2.5 mg SDL
Leuprorelin Acetate Injection 3.75 mg, 7.5 mg, 11.25 mg, 22.5 mg, 30 mg, 45 mg, 5 mg/mL MAF LHRH agonist is recommended:
1) As primary therapy for men with locally advanced or metastatic prostate cancer
2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy
3) For men with prostate cancer who have a biochemical relapse
LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer
Levetiracetam Concentrate for infusion 100 mg/mL MAF 1) As a 2nd line agent for the management of epilepsy in adults and children
2) As adjunctive therapy or monotherapy in patients who have inadequate seizure control or intolerable adverse effects with 1st line agents, or where the use of 1st line agents is contraindicated
Levetiracetam Oral solution 100 mg/mL MAF 1) As a 2nd line agent for the management of epilepsy in adults and children
2) As adjunctive therapy or monotherapy in patients who have inadequate seizure control or intolerable adverse effects with 1st line agents, or where the use of 1st line agents is contraindicated
Levetiracetam Tablet 250 mg, 500 mg, 1 g MAF 1) As a 2nd line agent for the management of epilepsy in adults and children
2) As adjunctive therapy or monotherapy in patients who have inadequate seizure control or intolerable adverse effects with 1st line agents, or where the use of 1st line agents is contraindicated
Levodopa & Benserazide Capsule Levodopa 100 mg + Benserazide 25 mg SDL
Levodopa & Benserazide Tablet Levodopa 200 mg + Benserazide 50 mg SDL
Levodopa & Benserazide Controlled-release capsule Levodopa 100 mg + Benserazide 25 mg SDL
Levodopa & Carbidopa Tablet Levodopa 100 mg + Carbidopa 25 mg, Levodopa 250 mg + Carbidopa 25 mg SDL
Levodopa & Carbidopa Sustained-release tablet Levodopa 200 mg + Carbidopa 50 mg SDL
Levodopa, Carbidopa & Entacapone Tablet Levodopa 50 mg + Carbidopa 12.5 mg + Entacapone 200 mg, Levodopa 100 mg + Carbidopa 25 mg + Entacapone 200 mg, Levodopa 150 mg + Carbidopa 37.5 mg + Entacapone 200 mg, Levodopa 200 mg + Carbidopa 50 mg + Entacapone 200 mg SDL
Levonorgestrel & Ethinylestradiol Tablet Levonorgestrel 0.15 mg + Ethinylestradiol 0.03 mg SDL
Levothyroxine Sodium Tablet 25 mcg, 50 mcg, 75 mcg, 100 mcg SDL
Lidocaine Ointment 5% SDL
Lidocaine Topical solution 4% SDL
Lidocaine Topical spray 10% SDL
Lidocaine & Adrenaline Injection Lidocaine 2% + Adrenaline 1:80,000 (12.5 microgram/mL) SDL
Lidocaine & Prilocaine Cream Lidocaine 2.5% + Prilocaine 2.5% SDL
Lidocaine Hydrochloride Gel 2% SDL
Lidocaine Hydrochloride Injection 1%, 10% SDL
Lidocaine Hydrochloride Oral solution (viscous) 2% SDL
Lidocaine Hydrochloride Injection (preservative-free) 1%, 1.5%, 2%, 10% SDL
Linagliptin Tablet 5 mg MAF For patients with type 2 diabetes mellitus and chronic kidney disease stages 3b, 4 or 5
LinezolidInfusion2 mg/mLMAFTreatment of patients with culture-positive vancomycin-resistant enterococci (VRE) bloodstream infections
LinezolidTablet600 mgMAFTreatment of patients with culture-positive vancomycin-resistant enterococci (VRE) bloodstream infections
Liothyronine Sodium Tablet 20 mcg SDL
Liquid Paraffin Oral emulsion 2.5 mL/5 mL SDL
Liquid Paraffin Liquid - SDL
Lisinopril Tablet 5 mg, 10 mg, 20 mg SDL
Lithium Carbonate Controlled-release tablet 400 mg SDL
Lomustine Capsule 40 mg SDL
Loratadine Syrup 5 mg/5 mL SDL
Loratadine Tablet 10 mg SDL
Lorazepam Tablet 0.5 mg, 1 mg SDL
Losartan Potassium Tablet 50 mg, 100 mg SDL
Lovastatin Tablet 20 mg SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Magnesium Carbonate & Sodium Bicarbonate Oral suspension Magnesium Carbonate 150 mg/5 mL + Sodium Bicarbonate 250 mg/5 mL + Aromatic Cardamon Tincture 0.15 mL/5 mL SDL
Magnesium Chloride Hexahydrate, Potassium Chloride & Procaine Hydrochloride Concentrate for infusion Magnesium Chloride Hexahydrate 162.5 mg/mL (0.8 mmol/mL) + Potassium Chloride 59.5 mg/mL (0.8 mmol/mL) + Procaine Hydrochloride 13.64 mg/mL (0.05 mmol/mL) SDL
Magnesium SulfateCrystal -SDL 
Magnesium Sulfate Injection 49.3% SDL
Magnesium Sulfate Injection 49.3% (2 mmol Mg2+/mL) SDL
Magnesium Sulfate & GlycerinSyrupMagnesium Sulfate 35.4% + Glycerin 1.1%
SDL 
Magnesium Trisilicate Oral suspension Magnesium Trisilicate 5% + Magnesium Carbonate 5% + Sodium Bicarbonate 5% Oral Suspension SDL
Malathion Lotion 0.5% SDL
Mannitol Infusion 20% SDL
Measles, Mumps, Rubella Vaccine Injection Measles Virus Vaccine (live-attenuated) minimum 1,000 CCID50/0.5 mL + Mumps Virus Vaccine (live-attenuated) minimum 12,500 CCID50/0.5 mL + Rubella Virus Vaccine (live-attenuated) minimum 1,000 CCID50/0.5 mL SDL
Mebeverine Hydrochloride Tablet 135 mg SDL
Medroxyprogesterone Acetate Injection 50 mg/mL SDL
Medroxyprogesterone Acetate Tablet 5 mg, 10 mg SDL
Mefenamic Acid Capsule 250 mg SDL
Mefloquine Tablet 250 mg SDL
Melphalan Injection 50 mg SDL
Melphalan Tablet 2 mg SDL
Mercaptopurine Tablet 50 mg SDL
Meropenem Injection 500 mg, 1 g SDL
Mesalazine Enema 2 g/30 mL SDL
Mesalazine Enteric-coated tablet 250 mg, 400 mg, 500 mg, 800 mg SDL
Mesalazine Slow-release tablet 500 mg SDL
Mesalazine Suppository 250 mg, 500 mg, 1 g SDL
Mesna Injection 100 mg/mL SDL
Mesna Tablet 400 mg, 600 mg SDL
Metformin Hydrochloride Tablet 250 mg, 500 mg, 850 mg SDL
Methadone Tablet 5 mg SDL
Methionine Oral powder - SDL
Methotrexate Injection 50 mg/2 mL, 1 g/10 mL SDL
Methotrexate Injection (preservative-free) 50 mg/2 mL SDL
Methotrexate Tablet 2.5 mg SDL
Methoxsalen Lotion 0.01%, 0.05%, 0.1%, 0.75% SDL
Methoxsalen Capsule 10 mg SDL
Methoxsalen Tablet 10 mg SDL
Methyl Salicylate Cream 10%-20% SDL
Methyl Salicylate Solution 25% SDL
Methylated Spirit Topical solution 70% SDL
Methyldopa Tablet 125 mg, 250 mg SDL
Methylphenidate Hydrochloride Extended-release tablet 18 mg, 27 mg, 36 mg, 54 mg MAF Attention deficit hyperactivity disorder in children and adolescents aged < 18 years old
Methylphenidate HydrochlorideLong-acting capsule20 mgMAFAttention deficit hyperactivity disorder in children and adolescents aged < 18 years old
Methylphenidate Hydrochloride Modified-release capsule 5 mg, 10 mg, 20 mg, 30 mg, 40 mg MAF Attention deficit hyperactivity disorder in children and adolescents aged < 18 years old
Methylphenidate Hydrochloride Sustained-release tablet 20 mg MAF Attention deficit hyperactivity disorder in children and adolescents aged < 18 years old
Methylphenidate Hydrochloride Tablet 10 mg SDL
Methylprednisolone (as Sodium Succinate) Injection 62.5 mg/mL SDL
Metoclopramide Hydrochloride Injection 5mg/mL SDL
Metoclopramide Hydrochloride Tablet 10 mg SDL
Metronidazole Infusion 5 mg/mL SDL
Metronidazole Tablet 200 mg SDL
Miconazole Oral gel 2% SDL
Miconazole Nitrate Cream 2% SDL
Midazolam Injection 5 mg/mL, 5 mg/5 mL SDL
Midodrine Hydrochloride Tablet 5 mg SDL
Mirtazapine Oral disintegrating tablet 15 mg, 30 mg SDL
Mirtazapine Tablet 30 mg SDL
Mitomycin Injection 2 mg, 10 mg SDL
Mitoxantrone Injection 2 mg/mL SDL
Moclobemide Tablet 150 mg SDL
Mometasone Furoate Nasal spray 0.05% SDL
Morphine Sulfate Controlled-release tablet 10 mg, 30 mg SDL
Morphine Sulfate Injection 10 mg/mL SDL
Morphine Sulfate Oral solution 10 mg/5 mL SDL
Morphine Sulfate Syrup 1 mg/mL SDL
Multivitamin for Paediatrics Oral solution A combination preparation of vitamins, minerals and/or nutrients, which includes at least 3 of the following: Ascorbic acid, Riboflavine, Nicotinamide, Thiamine, Pyridoxine, Calciferol, Cyanocobalamin, Vitamin A SDL
Mycophenolate MofetilCapsule250 mgMAFInduction and maintenance treatment of active lupus nephritis in patients who have biopsy-proven Class III, IV, V, or combinations of lupus nephritis based on International Society of Nephrology/Renal Pathology Society (ISN/RPS) criteria.

A renal biopsy should be performed as far as possible to confirm active lupus nephritis before starting treatment. If a renal biopsy is not possible, the following clinical criteria should be used to diagnose active lupus nephritis:
• Significant proteinuria of ≥1g per 24 hours; or
• Proteinuria ≥0.5g per 24 hours plus haematuria defined as ≥5 red blood cells per high power field; or
• Proteinuria ≥0.5g per 24 hours plus cellular casts
Mycophenolate MofetilTablet500 mgMAFInduction and maintenance treatment of active lupus nephritis in patients who have biopsy-proven Class III, IV, V, or combinations of lupus nephritis based on International Society of Nephrology/Renal Pathology Society (ISN/RPS) criteria.

A renal biopsy should be performed as far as possible to confirm active lupus nephritis before starting treatment. If a renal biopsy is not possible, the following clinical criteria should be used to diagnose active lupus nephritis:
• Significant proteinuria of ≥1g per 24 hours; or
• Proteinuria ≥0.5g per 24 hours plus haematuria defined as ≥5 red blood cells per high power field; or
• Proteinuria ≥0.5g per 24 hours plus cellular casts
Mydricaine Ophthalmic solution Atropine Sulfate 0.34% + Cocaine HCl 2% + Adrenaline 0.034% + Sodium Chloride 0.26% SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Nalidixic Acid Tablet 500 mg SDL
Naloxone Hydrochloride Injection 0.4 mg/mL, 0.02 mg/mL SDL
Nandrolone Decanoate Injection 25 mg/mL SDL
Naphazoline Hydrochloride & Pheniramine Maleate Eye drops Naphazoline Hydrochloride 0.025% + Pheniramine Maleate 0.3% SDL
Neomycin Sulfate Tablet 500 mg SDL
Neomycin, Polymyxin B & Dexamethasone Ear drops Neomycin Sulfate 6,500 international units/mL + Polymyxin B Sulfate 10,000 international units/mL + Dexamethasone Sodium Metasulfobenzoate 1 mg/mL SDL
Neostigmine Metilsulfate Injection 0.5 mg/mL, 2.5 mg/mL SDL
Netupitant & PalonosetronCapsuleNetupitant 300 mg & Palonosetron 0.5 mgMAFPrevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
Nicotinic Acid Tablet 50 mg SDL
Nifedipine Extended-release tablet 30 mg, 60 mg SDL
Nifedipine Tablet 5 mg, 10 mg SDL
Nifedipine Capsule 5 mg, 10 mg SDL
Nitrazepam Tablet 5 mg SDL
Nitrofurantoin Tablet 50 mg SDL
Norepinephrine Concentrate for infusion 4 mg/4 mL SDL
Norethisterone Tablet 5 mg SDL
Nortriptyline Capsule 10 mg, 25 mg SDL
Nystatin Oral suspension 100,000 units/mL SDL
Nystatin Vaginal tablet 100,000 units SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Olanzapine Oral disintegrating tablet 5 mg, 10 mg SDL
Olanzapine Tablet 5 mg, 10 mg SDL
Olive Oil Ear drops - SDL
OmalizumabInjection150 mgMAFChecklist to be completed.
As an add-on therapy to H1-antihistamines for treating severe chronic spontaneous urticaria (CSU) in patients aged 12 years and older, with a mean weekly Urticaria Activity Score (UAS7) of 28 and above, despite the use of, or who are intolerant to, four-times registered dose of second generation non-sedating H1-antihistamines.

A maximum of six 300 mg doses of omalizumab should be administered for each treatment course. Re-treatment with omalizumab can be considered upon relapse for patients who achieve an adequate response during the previous treatment course. Adequate response to omalizumab is defined as a UAS7 score of six or below while on treatment.
Omeprazole Capsule 20 mg SDL
OmeprazoleInjection 40mgSDL 
Ondansetron Injection 2 mg/mL SDL
Ondansetron Tablet 8 mg SDL
Oral Rehydration Salts Effervescent tablet - SDL
Oral Rehydration Salts Oral powder for reconstitution - SDL
Oxaliplatin Concentrate for infusion 50 mg/10 mL, 100 mg/50 mL SDL
Oxaliplatin Infusion 50 mg, 100 mg SDL
Oxybutynin Chloride Tablet 5 mg SDL
Oxymetazoline Hydrochloride Nasal drops 0.01%, 0.025%, 0.05% SDL
Oxymetazoline Hydrochloride Nasal spray 0.025%, 0.05% SDL
Oxytocin Injection 10 international units/mL SDL
Oxytocin & Ergometrine Maleate Injection Oxytocin 5 international units/mL + Ergometrine Maleate 0.5 mg/mL SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Paclitaxel Concentrate for infusion 6 mg/mL SDL
Pamidronate Disodium Infusion 30 mg, 90 mg MAF 1) Treatment of metastatic bone lesions from breast cancer and advanced multiple myeloma
2) Treatment of hypercalcaemia of malignancy
Pancuronium Bromide Concentrate for infusion 2 mg/mL SDL
PantopazoleInjection40 mgSDL 
Paracetamol Infusion 500 mg/50 mL, 1,000 mg/100 mL SDL
Paracetamol Oral suspension 120 mg/5 mL SDL
Paracetamol Rectal suppository 125 mg, 250 mg, 325 mg, 650 mg SDL
Paracetamol Tablet 120 mg, 500 mg SDL
Paracetamol & Orphenadrine Citrate Tablet Paracetamol 450 mg + Orphenadrine Citrate 35 mg SDL
Paraffin Liquid - SDL
Paraffin Soft & Paraffin Liquid Emulsion Soft Paraffin 50% + Liquid Paraffin 50% SDL
Peginterferon Alfa-2a Injection 135 mcg/0.5 mL, 180 mcg/0.5 mL MAF 1) Treatment, in combination with ribavirin, of chronic hepatitis C infection in naive adult patients and patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin
2) Treatment for a duration of up to 48 weeks, in adult patients with HBeAg-positive and HBeAg-negative chronic hepatitis B infection with compensated liver disease and evidence of viral replication and liver inflammation.
Peginterferon Alfa-2b Injection 50 mcg/0.5 mL, 80 mcg/0.5 mL, 100 mcg/0.5 mL, 120 mcg/0.5 mL, 150 mcg/0.5 mL MAF Treatment, in combination with ribavirin, of chronic hepatitis C infection in naïve adult patients and patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin
Penicillamine Capsule 250 mg SDL
Pethidine Hydrochloride Injection 50 mg/mL SDL
Phenazopyridine Hydrochloride Tablet 100 mg SDL
Phenobarbital Sodium Injection 20 mg/0.5 mL SDL
Phenobarbitone Tablet 10 mg, 30 mg, 60 mg SDL
Phenol (in almond oil) Injection 5% SDL
Phenoxymethylpenicillin Tablet 250 mg SDL
Phenylephrine Hydrochloride Single-use eye drops 2.5%, 10% SDL
Phenylephrine Hydrochloride Eye drops 2.5%, 10% SDL
Phenytoin Oral suspension 125 mg/5 mL SDL
Phenytoin Sodium Injection 50 mg/mL SDL
Phenytoin Sodium Capsule 30 mg, 100 mg SDL
Phosphate Buffer Powder - SDL
Physostigmine Salicylate Injection 1 mg/mL SDL
Phytomenadione Injection 10 mg/mL SDL
Pilocarpine Hydrochloride Eye drops 1%, 2%, 4% SDL
Pilocarpine Nitrate Single-use eye drops 2% SDL
Piperacillin & Tazobactam Injection Piperacillin 4 g + Tazobactam 0.5 g SDL
Pipotiazine Palmitate Injection 50 mg/mL SDL
Piroxicam Capsule 10 mg, 20 mg SDL
Plasma-derived Factor VIIIInjection250 international units, 500 international units, 1000 international unitsSDL 
Plasma-derived Factor VIII & Von Willebrand FactorInjectionPlasma-derived Factor VIII 250 international units, 500 international units, 1000 international units + Von Willebrand Factor range 100 international units to 3200 international unitsSDL 
Podophyllum Resin Paint 0.25%, 0.5% SDL
Poliomyelitis Vaccine (live-attenuated) Oral suspension Poliovirus Vaccine (type 1 live-attenuated) minimum 1,000,000 TCID50/0.5 mL + Poliovirus Vaccine (type 2 live-attenuated) minimum 100,000 TCID50/0.5 mL + Poliovirus Vaccine (type 3 live-attenuated) minimum 300,000 TCID50/0.5 mL SDL
Posaconazole Delayed-release tablet 100 mg MAF For prophylaxis of invasive fungal infections in high risk patients (such as anticipated to have prolonged neutropenia) and haematopoietic stem cell transplant recipients
Posaconazole Oral suspension 40 mg/mL MAF For prophylaxis of invasive fungal infections in high risk patients (such as anticipated to have prolonged neutropenia) and haematopoietic stem cell transplant recipients
Potassium Chloride Slow-release tablet 600 mg SDL
Potassium Chloride Oral solution 500 mg/5 mL SDL
Potassium Chloride Concentrate for infusion 7.45% SDL
Potassium Chloride Infusion 0.1 mmol/mL, 0.2 mmol/mL, 0.4 mmol/mL SDL
Potassium Chloride & Sodium Chloride Infusion Potassium Chloride 0.15% + Sodium Chloride 0.9% SDL
Potassium Citrate Oral solution 500 mg/5 mL SDL
Potassium Permanganate Crystals 100% SDL
Potassium Permanganate Topical solution 0.1% SDL
Potassium Phosphate Monobasic Concentrate for infusion 1 mmol/mL (0.1361 g/mL) SDL
Povidone-Iodine Topical solution 10% SDL
Pralidoxime Chloride Injection 500 mg/20 mL SDL
Pramipexole Dihydrochloride Monohydrate Tablet 0.125 mg, 1 mg SDL
Pravastatin Sodium Tablet 20 mg SDL
Prazosin Tablet 1 mg, 5 mg SDL
Prednisolone Syrup 10 mg/5 mL SDL
Prednisolone Tablet 1 mg, 5 mg, 20 mg SDL
Primaquine Tablet 7.5 mg, 15 mg SDL
Probenecid Tablet 500 mg SDL
Procainamide Hydrochloride Injection 100 mg/mL SDL
Procaine Hydrochloride Lotion (in spirit 70%) 2% SDL
Procarbazine Capsule 50 mg SDL
Prochlorperazine Maleate Tablet 5 mg SDL
Prochlorperazine Mesilate Injection 12.5 mg/mL SDL
Progesterone Injection 50 mg/mL SDL
Promethazine Hydrochloride Syrup 5 mg/5mL SDL
Promethazine Hydrochloride Injection 25 mg/mL SDL
Promethazine Hydrochloride Syrup 5 mg/5 mL SDL
Promethazine Theoclate Tablet 25 mg SDL
Propantheline Bromide Tablet 15 mg SDL
Proparacaine Hydrochloride Eye drops 0.5% SDL
Propofol Injection 10 mg/mL SDL
Propranolol Hydrochloride Injection 1 mg/mL SDL
Propranolol Hydrochloride Tablet 10 mg, 40 mg, 80 mg SDL
Propylene Glycol Solution 40% SDL
Propylene Glycol In Aqueous Cream Cream 20%, 40% SDL
Propylthiouracil Tablet 50 mg SDL
Protamine Sulfate Injection 1% (10 mg/mL) SDL
Pyrazinamide Tablet 500 mg SDL
Pyridostigmine Bromide Tablet 10 mg, 60 mg SDL
Pyridoxine Hydrochloride Tablet 10 mg, 50 mg SDL
Pyrimethamine Tablet 25 mg SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Quetiapine Tablet 25 mg, 100 mg, 200 mg SDL
Quinine Sulfate Tablet 300 mg SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Rabies Virus Vaccine (Inactivated) Injection Minimum 2.5 international units SDL
RanitidineInjection50 mg/2 mLSDL 
Recombinant Factor VIII (Xyntha)Injection250 international units, 500 international units, 1000 international units, 2000 international unitsSDL 
RibavirinCapsule200 mgMAFTreatment of chronic hepatitis C infection (all genotypes)
RibavirinTablet200 mgMAFTreatment of chronic hepatitis C infection (all genotypes)
Rifampicin Capsule 150 mg, 300 mg SDL
RifaximinTablet550 mgSDL 
Risedronate Sodium Tablet 5 mg, 35 mg MAF 1) For patients with osteoporosis (T-score ≤ -2.5)
2) For patients with osteopenia (T-score ≤ -1.5) and a history of non-trauma induced fracture
Risperidone Oral solution 1 mg/mL SDL
Risperidone Tablet 0.5 mg, 1 mg, 2 mg SDL
Rituximab Concentrate for infusion 100 mg/10 mL, 500 mg/50 mL MAF 1) Treatment of patients with CD20 positive diffuse large B cell lymphoma
2) Treatment of patients with CD20 positive follicular non-Hodgkin's lymphoma
Rivaroxaban Tablet 15 mg, 20 mg MAF 1) Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)* and CHA2DS2-VASc score of 1 or more for men, and 2 or more for women
*This excludes patients with rheumatic mitral stenosis or prosthetic heart valves
2) Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE in adults. MAF assistance does not apply to patients with isolated distal DVT
Rivastigmine Transdermal patch 4.6 mg/24 hr, 9.5 mg/24 hr, 13.3 mg/24 hr MAF Checklist to be completed
1) Rivastigmine patch formulation (4.6 mg/24 hr and 9.5 mg/24 hr) for the treatment of moderately severe dementia associated with Parkinson's disease in patients who have behavioural symptoms
2) Rivastigmine patch formulation (4.6 mg/24 hr, 9.5 mg/24 hr and 13.3 mg/24 hr) for the treatment of moderately severe dementia associated with Alzheimer's disease in patients who have behavioural symptoms
Ropinirole Tablet 0.25 mg, 1 mg, 2 mg SDL
Rubella Virus Vaccine (live-attenuated) Injection Minimum 1,000 TCID 50/0.5 mL SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Salbutamol Inhaler 100 mcg/dose SDL
Salbutamol Nebulisation solution 0.5% SDL
Salbutamol Concentrate for infusion 5 mg/5 mL SDL
Salbutamol Oral liquid 2 mg/5 mL SDL
Salbutamol Tablet 2 mg SDL
Salicylic Acid Cream 2%, 20% SDL
Salicylic Acid Ointment 1%, 2%, 5%, 10%, 20%, 40% SDL
Salicylic Acid & Lactic Acid Topical solution Salicylic Acid 16.7% + Lactic Acid 16.7% Collodion, Salicylic Acid 17% + Lactic Acid 17% Collodion SDL
Salmeterol & Fluticasone Propionate Inhaler Salmeterol 25 mcg/dose + Fluticasone Propionate 50 mcg/dose, Salmeterol 25 mcg/dose + Fluticasone Propionate 125 mcg/dose, Salmeterol 25 mcg/dose + Fluticasone Propionate 250 mcg/dose SDL
Salmeterol & Fluticasone Propionate Powder inhaler Salmeterol 50 mcg/dose + Fluticasone Propionate 100 mcg/dose, Salmeterol 50 mcg/dose + Fluticasone Propionate 250 mcg/dose, Salmeterol 50 mcg/dose + Fluticasone Propionate 500 mcg/dose SDL
Sea Snake Venom Antiserum Concentrate for infusion 1,000 units/dose SDL
Selenium Sulfide Topical suspension 2.5% SDL
Sennosides Tablet 7.5 mg SDL
Sertraline Tablet 50 mg SDL
Sevelamer CarbonateTablet800 mgMAFTreatment of hyperphosphataemia in patients with chronic kidney disease who have persistent hyperphosphataemia despite optimising treatment with calcium-based phosphate binders, or who are unable to tolerate calcium-based phosphate binders due to hypercalcaemia.
Silicone Cream Cream Dimethicone 10%, Chlorocresol 0.1% SDL
Simeticone Oral suspension 100 mg/mL SDL
Simvastatin Tablet 10 mg, 20 mg SDL
Sirolimus Tablet 0.5 mg, 1 mg, 2 mg MAF For kidney transplant immunosuppression in patients with:
1) Evidence of CNI-induced nephrotoxicity on allograft biopsy OR
2) Elevated serum creatinine levels precluding the achievement of optimal therapeutic blood levels of CNI OR
3) History of CNI drug hypersensitivity
Sirolimus Oral solution 1 mg/mL MAF For kidney transplant immunosuppression in patients with:
1) Evidence of CNI-induced nephrotoxicity on allograft biopsy OR
2) Elevated serum creatinine levels precluding the achievement of optimal therapeutic blood levels of CNI OR
3) History of CNI drug hypersensitivity
Sodium Alginate, Sodium Bicarbonate & Calcium Carbonate Oral suspension Sodium Alginate 500 mg/10 mL + Sodium Bicarbonate 267 mg/10 mL + Calcium Carbonate 160 mg/10 mL SDL
Sodium Bicarbonate Infusion 4.2%, 8.4% SDL
Sodium Bicarbonate Injection 4.2%, 8.4% SDL
Sodium Bicarbonate Capsule 500 mg SDL
Sodium Bicarbonate Powder Minimum 99% SDL
Sodium Bicarbonate & Sodium Chloride Powder 9 parts Sodium Bicarbonate + 1 part Sodium Chloride SDL
Sodium Calcium Edetate Injection 200 mg/mL SDL
Sodium Chloride Infusion 0.45%, 0.9%, 3%, 20% SDL
Sodium Chloride Irrigation solution 0.9% SDL
Sodium Chloride Injection 0.45%, 0.9%, 3%, 20% SDL
Sodium Chloride Eye drops 0.9%, 5% SDL
Sodium Chloride Eye ointment 5% SDL
Sodium Chloride & Dextrose Sustained-release tablet Sodium Chloride 500 mg + Dextrose 200 mg SDL
Sodium Chloride, Calcium Chloride Dihydrate & Potassium Chloride Infusion Sodium Chloride 8.6 g/L + Calcium Chloride Dihydrate 0.33 g/L + Potassium Chloride 0.3 g/L SDL
Sodium Laurylsulfoacetate & Sodium Citrate Enema Sodium Laurylsulfoacetate 9 mg/mL + Sodium Citrate 90 mg/mL + Sorbitol 625 mg/mL SDL
Sodium Nitrite Injection 3% SDL
Sodium Nitroprusside Injection 10 mg/mL, 50mg/2ml SDL
Sodium Polystyrene Sulfonate Oral suspension 15 g/60 mL SDL
Sodium Polystyrene Sulfonate Powder for oral suspension 99% SDL
Sodium Tetradecyl Sulfate Injection 1%, 3% SDL
Sodium Thiosulfate Injection 25% SDL
Sodium Thiosulfate Oral solution 25% SDL
Sodium Thiosulfate Powder 50 g SDL
Sodium Valproate Controlled-release tablet 200 mg, 300 mg, 500 mg SDL
Sodium Valproate Enteric-coated tablet 200 mg SDL
Sodium Valproate Injection 400 mg SDL
Sodium Valproate Syrup 200 mg/5 mL SDL
Sofosbuvir & VelpatasvirTabletSofosbuvir 400 mg + Velpatasvir 100 mg MAFChecklist to be completed.
Treatment of chronic hepatitis C infection (all genotypes) in treatment-naïve, or pegylated interferon plus ribavirin (PR)-experienced or NS3/4A protease inhibitor (boceprevir, simeprevir, telaprevir)-experienced adults.

Sofosbuvir/velpatasvir should be used in line with the recommended treatment regimen and duration:
• 12 weeks’ treatment of sofosbuvir/velpatasvir for patients with hepatitis C virus (all genotypes) without cirrhosis or with compensated cirrhosis (Child-Pugh A). For patients with genotype 3, the addition of ribavirin may be considered in patients who are treatment-experienced or have compensated cirrhosis (Child-Pugh A).
• 12 weeks’ treatment of sofosbuvir/velpatasvir in combination with ribavirin for patients with hepatitis C virus (all genotypes) with decompensated cirrhosis (Child-Pugh B or C).
Solifenacin SuccinateTablet 5 mg SDL  
Somatostatin (as Acetate) Infusion 3 mg SDL
Somatropin Prefilled pen 5 mg/1.5 mL, 10 mg/1.5 mL MAF Treatment of children with short stature due to conditions associated with growth failure
*Somatropin is not recommended for the treatment of idiopathic short stature
Somatropin Injection 3.33 mg, 4 mg, 6 mg MAF Treatment of children with short stature due to conditions associated with growth failure
*Somatropin is not recommended for the treatment of idiopathic short stature
Spironolactone Tablet 25 mg SDL
Streptokinase Infusion 1.5 million international units SDL
Streptomycin Injection 1 g, 5 g SDL
Sulfadiazine Silver Cream 1% SDL
Sulfamethoxazole & Trimethoprim Concentrate for infusion Sulfamethoxazole 80 mg/mL + Trimethoprim 16 mg/mL SDL
Sulfamethoxazole & Trimethoprim Suspension Trimethoprim 40 mg/5 mL + Sulphamethoxazole 200 mg/5 mL SDL
Sulfamethoxazole & Trimethoprim Tablet Trimethoprim 20 mg + Sulphamethoxazole 100 mg, Trimethoprim 80 mg + Sulphamethoxazole 400 mg SDL
Sulfasalazine Enteric-coated tablet 500 mg SDL
Sulphur & Salicylic Acid Cream Sulphur 4% + Salicylic Acid 2% SDL
Sulphur, Resorcinol & Calamine Lotion Sulphur 4% + Resorcinol 2% + Calamine 10% SDL
Sulphur, Zinc Oxide, Resorcinol & Calamine Cream Sulphur 4% + Zinc Oxide 8% + Resorcinol 2% + Calamine 8% SDL
Sulpiride Tablet 200 mg SDL
Sumatriptan Tablet 50 mg SDL
Suxamethonium Chloride Injection 50 mg/mL SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Tacrolimus Prolonged-release capsule 0.5 mg, 1 mg, 5 mg SDL
Tacrolimus Capsule 0.5 mg, 1 mg, 5 mg SDL
Tacrolimus Ointment 0.1% MAF Treatment of moderate to severe atopic dermatitis in adults and adolescents (16 years of age and above) who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids
Tacrolimus Ointment 0.03% MAF 1) Treatment of moderate to severe atopic dermatitis in adults and adolescents (16 years of age and above) who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids
2) Treatment of moderate to severe atopic dermatitis in children (2 years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids
Tamoxifen Tablet 10 mg, 20 mg SDL
TelmisartanTablet40 mg, 80 mgSDL 
Temozolomide Capsule 20 mg, 100 mg SDL
Tenofovir Disoproxil Fumarate Tablet 300 mg MAF Treatment of patients with chronic hepatitis B infection for whom nucleos(t)ide analogue therapy is indicated, whether treatment-naïve or experienced
Terazosin Tablet 2 mg, 5 mg SDL
Testosterone Cipionate Injection 100 mg/mL SDL
Tetanus Immunoglobulin (Human) Injection 250 units/dose SDL
Tetanus Toxoid Vaccine Injection Minimum 40 international units/0.5 mL SDL
Tetracycline Hydrochloride Ointment 3% SDL
Tetracycline Hydrochloride Capsule 250 mg SDL
Theophylline Sustained-release tablet 125 mg, 200 mg, 250 mg, 300 mg SDL
Theophylline Syrup 80 mg/15 mL SDL
Theophylline Tablet 125 mg SDL
Thiamine Hydrochloride Injection 100 mg/2 mL, 100 mg/mL SDL
Thiamine Hydrochloride Tablet 10 mg SDL
Thiopental Sodium Injection 0.5 g, 1 g SDL
Thrombin Topical solution 5,000 international units/5 mL SDL
TicagrelorTablet90 mgMAF Prevention of thrombotic events (cardiovascular death, myocardial infarction and stroke) in adults with acute coronary syndromes, that is, people:
• with ST-segment-elevation myocardial infarction (STEMI); or
• with non-ST-segment-elevation myocardial infarction (NSTEMI); or
• with unstable angina requiring hospitalisation - defined as ST or T wave changes on electrocardiogram suggestive of ischaemia plus one of the following characteristics:
- age 60 years and older;
- previous myocardial infarction;
- previous coronary artery bypass grafting (CABG);
- coronary artery disease with stenosis of 50% or more in at least two vessels;
- previous ischaemic stroke;
- previous transient ischaemic attack;
- carotid stenosis of at least 50%;
- cerebral revascularisation;
- diabetes mellitus;
- peripheral arterial disease; or
- chronic renal dysfunction, defined as a creatinine clearance of less than 60 ml per minute per 1.73m2 of body surface area.

Ticagrelor should be used in combination with low-dose aspirin for up to 12 months.
Ticlopidine Hydrochloride Tablet 250 mg SDL
Timolol Maleate Eye drops 0.25%, 0.5% SDL
Tioguanine Tablet 40 mg SDL
Tolbutamide Tablet 500 mg SDL
Tolterodine Tartrate Extended-release capsule 4 mg SDL
Tolterodine Tartrate Tablet 1 mg, 2 mg SDL
Topiramate Tablet 25 mg, 50 mg, 100 mg SDL
Tramadol Hydrochloride Capsule 50 mg SDL
Tramadol Hydrochloride Tablet 50 mg SDL
Tranexamic Acid Injection 100 mg/mL SDL
Tranexamic Acid Tablet 500 mg SDL
Trastuzumab Infusion 440 mg MAF 1) Treatment of women with HER2-positive early breast cancer who are axillary lymph node positive
2) Treatment of women with HER2-positive early breast cancer with tumour size greater than 1 cm and are axillary lymph node negative
Checklist to be completed
3) Treatment of HER2-positive metastatic breast cancer, in the following circumstances:
In combination with a taxane for patients who have not received chemotherapy for their metastatic disease, or
In combination with an aromatase inhibitor for postmenopausal patients with hormone-receptor positive metastatic breast cancer, not previously treated with trastuzumab
Tretinoin Capsule 10 mg SDL
Triamcinolone Acetonide Injection 10 mg/mL SDL
Triamcinolone Acetonide Nasal spray 55 mcg/dose SDL
Triamterene & Hydrochlorothiazide Tablet Triamterene 50 mg + Hydrochlorothiazide 25 mg SDL
Trifluoperazine Tablet 1 mg, 5 mg SDL
Trimethoprim Oral suspension 50 mg/5 mL SDL
Trimethoprim Tablet 100 mg SDL
Tropicamide Eye drops 0.5%, 1% SDL
Tropicamide Single-use eye drops 1% SDL
Typhoid Vaccine (salmonella typhi Vi polysaccharide Ty2 strain) (Killed vaccine) Injection 25 mcg/0.5 mL SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Umeclidinium Powder inhaler 62.5 mcg/dose SDL
Umeclidinium & Vilanterol Powder inhaler Umeclidinium 62.5 mcg/dose + Vilanterol 25 mcg/dose SDL
Urea Cream 5%, 10% SDL
Ursodeoxycholic AcidCapsule250 mg SDL  
Ursodeoxycholic AcidTablet500 mg SDL  
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Valganciclovir Tablet 450 mg SDL Prevention of cytomegalovirus infection after solid organ transplant
Valsartan Tablet 80 mg, 160 mg SDL
Vancomycin Infusion 500 mg SDL
Vasopressin Injection 20 pressor units/mL SDL
Venlafaxine Extended-release capsule 75 mg, 150 mg SDL
Verapamil Hydrochloride Injection 2.5 mg/mL SDL
Verapamil Hydrochloride Tablet 40 mg SDL
Vinblastine Sulfate Injection 10 mg SDL
Vincristine Sulfate Injection 1 mg SDL
Vitamin A Capsule 10,000 units SDL
Vitamin B Complex Injection Thiamine Hydrochloride 10 mg/2 mL + Sodium Riboflavin Phosphate 4 mg/2 mL + Nicotinic Acid 40 mg/2 mL + Panthenol 6 mg/2 mL + Biotin 5 mg/2 mL + Pyridoxine Hydrochloride 4 mg/2 mL + Cyanocobalamin 8 mcg/2 mL SDL
Vitamin B Complex Tablet Thiamine 3 mg + Riboflavine 1.5 mg + Nicotinamide 10 mg + Pyridoxine 0.5 mg SDL
Voriconazole Infusion 200 mg MAF 1) Treatment of invasive aspergillosis
2) Treatment of candidaemia in non-neutropenic patients
3) Treatment of fluconazole-resistant candidiasis
4) Treatment of serious infections from Scedosporium and Fusarium species
Voriconazole Oral suspension 40 mg/mL MAF 1) Treatment of invasive aspergillosis
2) Treatment of candidaemia in non-neutropenic patients
3) Treatment of fluconazole-resistant candidiasis
4) Treatment of serious infections from Scedosporium and Fusarium species
Voriconazole Tablet 50 mg, 200 mg MAF 1) Treatment of invasive aspergillosis
2) Treatment of candidaemia in non-neutropenic patients
3) Treatment of fluconazole-resistant candidiasis
4) Treatment of serious infections from Scedosporium and Fusarium species
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Warfarin Sodium Tablet 1 mg, 3 mg, 5 mg SDL
White Soft Paraffin Ointment - SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Yellow Fever Virus Vaccine (live-attenuated) Injection Minimum 1,000 LD50 units SDL
Active Ingredient(s) Dosage Form Strength(s) Subsidy Class Clinical Indication (where applicable)
Zoledronic Acid Infusion 5 mg/100 mL MAF 1) For patients with osteoporosis (T score ≤ -2.5) and who are unable to tolerate or follow the administration instructions for oral bisphosphonates
2) For patients with FRAX of ≥ 20 for major osteoporotic fractures and ≥ 3 for hip fractures and who are unable to tolerate or follow the administration instructions for oral bisphosphonates
Zoledronic Acid Infusion 4 mg MAF 1) Treatment of metastatic bone lesions from solid tumours and multiple myeloma
2) Treatment of hypercalcaemia of malignancy
Zuclopenthixol Acetate Injection 50 mg/mL SDL
Zuclopenthixol Decanoate Injection 200 mg/mL SDL

Frequently Asked Questions

Expand All | Collapse All

What if my drug isn't listed?

In exceptional cases, MAF can also support HSA-registered drugs that are not on the SDL or MAF list, on a case-by-case basis.

How do I apply?

Please approach a Medical Social Worker (MSW) at the public acute hospital, specialist outpatient clinic or polyclinic where you are receiving treatment. They will be able to advise you further.